JP2024178159A5 - - Google Patents

Info

Publication number
JP2024178159A5
JP2024178159A5 JP2024135623A JP2024135623A JP2024178159A5 JP 2024178159 A5 JP2024178159 A5 JP 2024178159A5 JP 2024135623 A JP2024135623 A JP 2024135623A JP 2024135623 A JP2024135623 A JP 2024135623A JP 2024178159 A5 JP2024178159 A5 JP 2024178159A5
Authority
JP
Japan
Prior art keywords
compound
formula
composition according
approximately
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024135623A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024178159A (ja
Filing date
Publication date
Priority claimed from PCT/US2019/052161 external-priority patent/WO2020061458A1/en
Application filed filed Critical
Publication of JP2024178159A publication Critical patent/JP2024178159A/ja
Publication of JP2024178159A5 publication Critical patent/JP2024178159A5/ja
Pending legal-status Critical Current

Links

JP2024135623A 2018-09-21 2024-08-15 癌を治療する方法 Pending JP2024178159A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862734649P 2018-09-21 2018-09-21
US62/734,649 2018-09-21
PCT/US2019/052161 WO2020061458A1 (en) 2018-09-21 2019-09-20 Methods of treating cancer
JP2021540786A JP2022501441A (ja) 2018-09-21 2019-09-20 癌を治療する方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021540786A Division JP2022501441A (ja) 2018-09-21 2019-09-20 癌を治療する方法

Publications (2)

Publication Number Publication Date
JP2024178159A JP2024178159A (ja) 2024-12-24
JP2024178159A5 true JP2024178159A5 (https=) 2026-03-25

Family

ID=69887889

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021540786A Withdrawn JP2022501441A (ja) 2018-09-21 2019-09-20 癌を治療する方法
JP2024135623A Pending JP2024178159A (ja) 2018-09-21 2024-08-15 癌を治療する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021540786A Withdrawn JP2022501441A (ja) 2018-09-21 2019-09-20 癌を治療する方法

Country Status (9)

Country Link
US (1) US20220125957A1 (https=)
EP (1) EP3852816A4 (https=)
JP (2) JP2022501441A (https=)
KR (1) KR20210095620A (https=)
CN (4) CN113164631A (https=)
AU (2) AU2019345320B2 (https=)
CA (1) CA3112806A1 (https=)
IL (2) IL281600B2 (https=)
WO (1) WO2020061458A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016010927A2 (pt) 2013-11-14 2017-08-08 Endocyte Inc Conjugado de fórmula
US12208102B2 (en) 2018-04-17 2025-01-28 Endocyte, Inc. Methods of treating cancer
CN114096264B (zh) 2019-05-20 2025-03-14 因多塞特股份有限公司 制备psma缀合物的方法
US11129912B1 (en) 2020-07-13 2021-09-28 POINT Biopharma Inc. Radiopharmaceutical and methods
KR20240004205A (ko) 2020-07-13 2024-01-11 포인트 바이오파마 인코포레이티드 방사성의약 및 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140154702A1 (en) * 2012-11-30 2014-06-05 Endocyte, Inc. Methods For Treating Cancer Using Combination Therapies
LT4095130T (lt) * 2013-10-18 2024-04-25 Novartis Ag Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti
IL237525A (en) * 2015-03-03 2017-05-29 Shalom Eli Method for labeling a prostate-specific membrane antigen with a radioactive isotope
WO2017117687A1 (en) * 2016-01-10 2017-07-13 British Columbia Cancer Agency Branch 18/19f-labelled compounds which target the prostate specific membrane antigen
WO2018108287A1 (en) * 2016-12-15 2018-06-21 The European Atomic Energy Community (Euratom), Represented By The European Commission Treatment of pmsa expressing cancers
SG11202005511VA (en) * 2017-12-13 2020-07-29 Sciencons AS Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide

Similar Documents

Publication Publication Date Title
JP2024178159A5 (https=)
JP2022501441A5 (https=)
Nagaraju et al. Cyclooxygenase‐2 in gastrointestinal malignancies
Nemes et al. Gastrointestinal stromal tumor (GIST) associated with synchronous colon adenocarcinoma-a case report
Stark et al. Pancreatic ductal adenocarcinoma
JP2021514395A5 (https=)
Howard Pancreatic adenocarcinoma
Hsieh et al. Enhanced antitumour response of gold nanostar-mediated photothermal therapy in combination with immunotherapy in a mouse model of colon carcinoma
JP2019527740A5 (https=)
JPWO2020061458A5 (https=)
Zhang et al. 18F-FAPI-42 PET/CT enhances the diagnostic efficacy for peritoneal metastasis of colorectal cancer and guides treatment decisions: an original retrospective study
CA2483826A1 (en) Epothilone derivative for the treatment of hepatoma and other cancer diseases
Amore Bonapasta et al. Metastasis to the pancreas from breast cancer: difficulties in diagnosis and controversies in treatment
Neves et al. Extended survival after complete pathological response in metastatic pancreatic ductal adenocarcinoma following induction chemotherapy, chemoradiotherapy, and a novel immunotherapy agent, IMM-101
RU2021111125A (ru) Способы лечения рака
JPWO2021168028A5 (https=)
JPWO2023002045A5 (https=)
Han et al. Epigenetic modifications in follicular cell-derived thyroid cancer: new dimensions in pathogenesis and treatment
Yang et al. Long-term survival of a patient with pancreatic cancer and lung metastasis: A case report and review of literature
Liu et al. Case report: A case study of neoadjuvant immunochemotherapy for locally advanced esophageal squamous carcinoma
Iyer et al. Buccal mucosal metastasis of renal cell carcinoma: a case report and review of literature
Louredo et al. The first case report of metastatic rectal adenocarcinoma to the oral vestibule in a young woman
Valdés Correlation between symptoms and survival in patients with renal cell carcinoma
Hartung et al. New approaches to adjuvant therapy of colorectal carcinoma including current German activities
RU2492855C2 (ru) Способ комбинированного лечения немелкоклеточного рака легкого ii и iii стадии с пред- и послеоперационной химиотерапией